Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8WUD1
UPID:
RAB2B_HUMAN
Alternative names:
-
Alternative UPACC:
Q8WUD1; B2RD03; D3DS24; Q6NZ33
Background:
Ras-related protein Rab-2B plays a pivotal role in intracellular membrane trafficking, regulating the movement of vesicular carriers and maintaining organelle identity. It cycles between active and inactive states, influencing the Golgi's morphology and promoting innate immune responses against DNA viruses by modulating the CGAS-STING signaling axis.
Therapeutic significance:
Understanding the role of Ras-related protein Rab-2B could open doors to potential therapeutic strategies.